Use of MDMA & Psilocybin in the Treatment of PTSD - Camden Grant-Howard; Joel S. Steele (PDXScholar (Portland State University), 2018)

Psilocybin induces aberrant prediction error processing for tactile mismatch responses - P. Dürler (European Neuropsychopharmacology, 2018)

Peak experiences in a consciousness landscape - report on the science of consciousness conference in Interlaken, Switzerland, 2019 - Hans Liljenström (Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences)), 2018)

Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs - Edward James; Thomas L Robertshaw; Michael Pascoe; Fiona Chapman; Andrew D. Westwell; Andrew Smith (Drug Science Policy and Law, 2018)

Effects of psilocybin on functional connectivity measured with fNIRS: Insights from a single-subject pilot study - Felix Scholkmann; Lisa Holper; Katrin H. Preller; Franz X. Vollenweider (Zurich Open Repository and Archive (University of Zurich), 2018)

Multi-targeting cytotoxic drug leads from mushrooms - MVNL Chaitanya; Asha Jose; Prakash Ramalingam; Subhash C. Mandal; PNarendra Kumar (Asian Pacific Journal of Tropical Medicine, 2018)

2018: A watershed year for psychedelic science - Jacob S. Aday; Christopher C. Davoli; Emily K. Bloesch (Drug Science Policy and Law, 2018)

Microcrystal Tests for the Identification of Illicit Drugs: Phencyclidine, Pseudoephedrine, and Psilocin - Kelly M. Brinsko; Dean Golemis; Meggan B. King; Gary J. Laughlin; Sebastian B. Sparenga (The Microscope, 2018)

Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. - Dinis-Oliveira RJ; Pereira CL; da Silva DD. (2018)

Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. - Fadiman J; Korb S (Journal of psychoactive drugs, 2018)

Psychedelics as a treatment for disorders of consciousness - Gregory Scott; Robin Carhart-Harris (Neuroscience of Consciousness, 2018)

Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. - Hutten NRPW; Mason NL; Dolder PC; Kuypers KPC (Frontiers in psychiatry, 2018)

Second and third year medical students' self-reported alcohol and substance use, smoking habits and academic performance at a South African medical school. - Vorster A; Gerber AM; van der Merwe LJ; van Zyl S (Health SA = SA Gesondheid, 2018)

The ethics of psychedelic research in disorders of consciousness. - Peterson A; Tagliazucchi E; Weijer C (Neuroscience of consciousness, 2018)

Psilocybin occupancy of brain serotonin 2A receptors correlates with psilocin levels and subjective experience: a [11C]Cimbi-36 PET study in humans - M. Madsen; Daniel Burmester; Dea Siggaard Stenbæk; Søren Kristiansen; Agnete Dyssegaard; Szabolcs Lehel; Kristían Línnet; Sys Stybe Johansen; Claus Svarer; Brice Ozenne; David Erritzøe; Patrick M. Fisher; et al. (European Neuropsychopharmacology, 2018)

Acute renal injury cause by confirmed Psilocybe cubensis mushroom ingestion. - Austin E; Myron HS; Summerbell RK; Mackenzie C. (2018)

Unpredictable Behavior Under the Influence of "Magic Mushrooms": A Case Report and Review of the Literature. - Honyiglo E; Franchi A; Cartiser N; Bottinelli C; Advenier AS; Bévalot F; Fanton L. (2018)

Monoamine Biosynthesis via a Noncanonical Calcium-Activatable Aromatic Amino Acid Decarboxylase in Psilocybin Mushroom. - Torrens-Spence MP; Liu CT; Pluskal T; Chung YK; Weng JK. (2018)

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. - Barsuglia J; Davis AK; Palmer R; Lancelotta R; Windham-Herman AM; Peterson K; Polanco M; Grant R; Griffiths RR. (2018)

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. - Johnson MW; Hendricks PS; Barrett FS; Griffiths RR. (2018)

Production Options for Psilocybin: Making of the Magic. - Fricke J; Lenz C; Wick J; Blei F; Hoffmeister D. (2018)

Psychedelic drugs in the treatment of anxiety, depression and addiction. - Kvam TM; Stewart LH; Andreassen OA. (2018)

What Psilocybin Taught Me About Dying. - Back AL. (2018)

Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers - Anderson T; Petranker R; Rosenbaum D; Weissman C; Dinh-Williams L; Hui K; Hapke E; Farb NAS. (PsyArXiv, 2018)

Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers (PsyArXiv, 2018)

Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition. - Atasoy S; Vohryzek J; Deco G; Carhart-Harris RL; Kringelbach ML. (2018)

More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression. - Lyons T; Carhart-Harris RL. (2018)

DARK Classics in Chemical Neuroscience: Ibogaine. - Wasko MJ; Witt-Enderby PA; Surratt CK. (2018)

The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. - Jalal B. (2018)

Iterative l-Tryptophan Methylation in Psilocybe Evolved by Subdomain Duplication. - Blei F; Fricke J; Wick J; Slot JC; Hoffmeister D. (2018)

Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain. - Müller F; Liechti ME; Lang UE; Borgwardt S. (2018)

Dimensions of consciousness and the psychedelic state. - Bayne T; Carter O. (2018)

Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. - Leonard JB; Anderson B; Klein-Schwartz W. (2018)

Psychedelics, Meditation, and Self-Consciousness. - Millière R; Carhart-Harris RL; Roseman L; Trautwein FM; Berkovich-Ohana A. (2018)

Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats. - Horsley RR; Páleníček T; Kolin J; Valeš K. (2018)

d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. - De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G. (2018)

Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. - Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC. (2018)

Psychedelic fungus (Psilocybe sp.) authentication in a case of illegal drug traffic: sporological, molecular analysis and identification of the psychoactive substance. - Solano J; Anabalón L; Figueroa S; Lizama C; Reyes LC; Gangitano D. (2018)

Psychedelics as anti-inflammatory agents. - Flanagan TW; Nichols CD. (2018)

Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. - Ross S. (2018)

Psychedelics and music: neuroscience and therapeutic implications. - Barrett FS; Preller KH; Kaelen M (International review of psychiatry (Abingdon, England), 2018)

Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. - Hendricks PS (International review of psychiatry (Abingdon, England), 2018)

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. - Garcia-Romeu A; Richards WA (International review of psychiatry (Abingdon, England), 2018)

Mushroom Poisoning Cases in Dogs and Cats: Diagnosis and Treatment of Hepatotoxic, Neurotoxic, Gastroenterotoxic, Nephrotoxic, and Muscarinic Mushrooms. - Puschner B; Wegenast C. (2018)

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. - Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR. (2018)

Altered trajectories in the dynamical repertoire of functional network states under psilocybin - Lord L; Expert P; Atasoy S; Roseman L; Rapuano K; Lambiotte R; Nutt DJ; Deco G; Carhart-Harris RL; Kringelbach ML; Cabral J. (bioRxiv, 2018)

Convergent evolution of psilocybin biosynthesis by psychedelic mushrooms - Awan AR; Winter JM; Turner D; Shaw WM; Suz LM; Bradshaw AJ; Ellis T; Dentinger BT. (bioRxiv, 2018)

Psychoactive plant- and mushroom-associated alkaloids from two behavior modifying cicada pathogens - Boyce GR; Gluck-Thaler E; Slot JC; Stajich JE; Davis WJ; James TY; Cooley JR; Panaccione DG; Eilenberg J; Licht HHDF; Macias AM; Berger MC; et al. (bioRxiv, 2018)

Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT). - Cameron LP; Olson DE. (2018)

Psychopharmacology of Psilocybin in Cancer Patients - Johns Hopkins University (ClinicalTrials.gov, 2018)

DARK Classics in Chemical Neuroscience: Psilocybin. - Geiger HA; Wurst MG; Daniels RN. (2018)

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. - Schenberg EE. (2018)

Psilocybin and Mental Health-Don't Lose Control. - Barnby JM; Mehta MA. (2018)

Hallucinogen persisting perception disorder: A literature review and three case reports. - Skryabin VY; Vinnikova M; Nenastieva A; Alekseyuk V. (2018)

High dose psilocybin is associated with positive subjective effects in healthy volunteers. - Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR. (2018)

Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. - Noorani T; Garcia-Romeu A; Swift TC; Griffiths RR; Johnson MW. (2018)

Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase-Enhanced Reactions. - Blei F; Baldeweg F; Fricke J; Hoffmeister D. (2018)

Effects of psilocybin therapy on personality structure. - Erritzoe D; Roseman L; Nour MM; MacLean K; Kaelen M; Nutt DJ; Carhart-Harris RL. (2018)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. - Johnson MW; Griffiths RR; Hendricks PS; Henningfield JE. (2018)

Psychedelics and Personality. - Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC. (2018)

Biological Effects and Biodistribution of Bufotenine on Mice. - Vigerelli H; Sciani JM; Eula MAC; Sato LA; Antoniazzi MM; Jared C; Pimenta DC. (2018)

Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. - Gabay AS; Carhart-Harris RL; Mazibuko N; Kempton MJ; Morrison PD; Nutt DJ; Mehta MA. (2018)

Psychedelic use and intimate partner violence: The role of emotion regulation. - Thiessen MS; Walsh Z; Bird BM; Lafrance A. (2018)

Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi. - Hoefgen S; Lin J; Fricke J; Stroe MC; Mattern DJ; Kufs JE; Hortschansky P; Brakhage AA; Hoffmeister D; Valiante V. (2018)

Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? - Whelan A; Johnson MI. (2018)

Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. - Grimm O; Kraehenmann R; Preller KH; Seifritz E; Vollenweider FX. (2018)

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. - Malone TC; Mennenga SE; Guss J; Podrebarac SK; Owens LT; Bossis AP; Belser AB; Agin-Liebes G; Bogenschutz MP; Ross S. (2018)

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. - Carrillo F; Sigman M; Fernández Slezak D; Ashton P; Fitzgerald L; Stroud J; Nutt DJ; Carhart-Harris RL. (2018)

Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). - Ramachandran V; Chunharas C; Marcus Z; Furnish T; Lin A. (2018)

Ceremonial "plant medicine" use and its relationship to recreational drug use: an exploratory study. - Dorsen C; Palamar J; Shedlin MG. (2018)

Out of the box: A psychedelic model to study the creative mind. - Kuypers KPC. (2018)

"Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. - Barrett FS; Schlienz NJ; Lembeck N; Waqas M; Vandrey R. (2018)

Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD). - Nichols DE. (2018)

Horizontal gene cluster transfer increased hallucinogenic mushroom diversity. - Reynolds HT; Vijayakumar V; Gluck-Thaler E; Korotkin HB; Matheny PB; Slot JC. (2018)

The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. - Nielson EM; May DG; Forcehimes AA; Bogenschutz MP. (2018)

Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. - Bogenschutz MP; Podrebarac SK; Duane JH; Amegadzie SS; Malone TC; Owens LT; Ross S; Mennenga SE. (2018)

The hidden therapist: evidence for a central role of music in psychedelic therapy. - Kaelen M; Giribaldi B; Raine J; Evans L; Timmerman C; Rodriguez N; Roseman L; Feilding A; Nutt D; Carhart-Harris R. (2018)

Taking Psychedelics Seriously. - Byock I. (2018)

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. - Roseman L; Nutt DJ; Carhart-Harris RL. (2018)

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. - Lyons T; Carhart-Harris RL. (2018)

Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers. - Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; et al. (2018)

Integration and segregation in whole-brain networks: implications for altered states of consciousness - Lord L. (University of Oxford, 2017)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations. - Kometer M; Vollenweider FX. (2017)

Phenomenology, Structure, and Dynamic of Psychedelic States. - Preller KH; Vollenweider FX (Current topics in behavioral neurosciences, 2017)

Effect of Hallucinogens on Unconditioned Behavior. - Halberstadt AL; Geyer MA (Current topics in behavioral neurosciences, 2017)

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. - Barrett FS; Griffiths RR. (2017)

Therapeutic Applications of Classic Hallucinogens. - Bogenschutz MP; Ross S. (2017)

The Effects of Hallucinogens on Gene Expression. - Martin DA; Nichols CD. (2017)

Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways. - López-Giménez JF; González-Maeso J. (2017)

Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens. - Sherwood AM; Prisinzano TE (Expert review of clinical pharmacology, 2017)

Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. - Canal CE. (2017)

Unifying Theories of Psychedelic Drug Effects. - Swanson LR (Frontiers in pharmacology, 2017)

Mushroom poisoning epidemiology in the United States. - Brandenburg WE; Ward KJ (Mycologia, 2017)

Rapid-Acting Antidepressants. - Witkin JM; Knutson DE; Rodriguez GJ; Shi S. (2017)

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. - Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL. (2017)

Psychiatry & the psychedelic drugs. Past, present & future. - Rucker JJH; Iliff J; Nutt DJ. (2017)

Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression - University of Helsinki (ClinicalTrials.gov, 2017)

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. - Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR. (2017)

Analysis of new psychoactive substances in oral fluids by means of microextraction by packed sorbent followed by ultra-high-performance liquid chromatography-tandem mass spectrometry. - Rocchi R; Simeoni MC; Montesano C; Vannutelli G; Curini R; Sergi M; Compagnone D. (2017)

The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. - Orsolini L; Papanti GD; De Berardis D; Guirguis A; Corkery JM; Schifano F. (2017)

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. - Kraehenmann R; Pokorny D; Aicher H; Preller KH; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX. (2017)

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. - Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; et al. (2017)

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. - Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR. (2017)

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. - Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL. (2017)

The relationships of classic psychedelic use with criminal behavior in the United States adult population. - Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G. (2017)

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. - Carhart-Harris RL; Roseman L; Bolstridge M; Demetriou L; Pannekoek JN; Wall MB; Tanner M; Kaelen M; McGonigle J; Murphy K; Leech R; Curran HV; et al. (2017)

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. - Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA. (2017)

TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT2A receptor pharmacological tool, or none of the above? - Di Giovanni G; De Deurwaerdère P. (2017)

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. - Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME (Clinical pharmacokinetics, 2017)

Psychedelic Drugs in Biomedicine. - Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV. (2017)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. - Reiche S; Hermle L; Gutwinski S; Jungaberle H; Gasser P; Majić T. (2017)

Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. - Andersson M; Persson M; Kjellgren A. (2017)

Effect of Psilocybin on Empathy and Moral Decision-Making. - Pokorny T; Preller KH; Kometer M; Dziobek I; Vollenweider FX. (2017)

Enzymatic Synthesis of Psilocybin. - Fricke J; Blei F; Hoffmeister D. (2017)

Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. - Sellers EM; Leiderman DB. (2017)

The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. - Sessa B. (2017)

Could Hallucinogens Induce Permanent Pupillary Changes in (Ab)users? A Case Report from New Zealand. - Al-Imam A. (2017)

Horizontal gene cluster transfer increased hallucinogenic mushroom diversity - Reynolds HT; Vijayakumar V; Gluck-Thaler E; Korotkin HB; Matheny PB; Slot JC. (bioRxiv, 2017)

Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions. - Barrett FS; Robbins H; Smooke D; Brown JL; Griffiths RR. (2017)

Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. - Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX. (2017)

LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark. - Larsen JK. (2017)

Potential Therapeutic Effects of Psilocybin. - Johnson MW; Griffiths RR. (2017)

[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. - Majić T; Jungaberle H; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J. (2017)

Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. - Forstmann M; Sagioglou C. (2017)

Neuroticism is associated with challenging experiences with psilocybin mushrooms. - Barrett FS; Johnson MW; Griffiths RR. (2017)

Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice. - Fabregat-Safont D; Barneo-Muñoz M; Martinez-Garcia F; Sancho JV; Hernández F; Ibáñez M. (2017)

Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia. - Strauss N. (2017)

Psilocybin: Good Trip or Bad Trip. - Sellers EM. (2017)

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders. - Thomas K; Malcolm B; Lastra D. (2017)

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. - Carhart-Harris RL; Goodwin GM. (2017)

Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. - Schartner MM; Carhart-Harris RL; Barrett AB; Seth AK; Muthukumaraswamy SD. (2017)

No clinically relevant effects in children after accidental ingestion of Panaeolina foenisecii (lawn mower's mushroom). - Schenk-Jaeger KM; Hofer-Lentner KE; Plenert B; Eckart D; Haberl B; Schulze G; Borchert-Avalone J; Stedtler U; Pfab R (Clinical toxicology (Philadelphia, Pa.), 2017)

Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. - Dos Santos RG; Bouso JC; Hallak JEC. (2017)

Designer Drugs 2.0. - Huestis MA; Tyndale RF. (2017)

Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. - Dinis-Oliveira RJ. (2017)

The fibrinolytic system: A new target for treatment of depression with psychedelics. - Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S. (2017)

An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. - Johnson MW; Garcia-Romeu A; Johnson PS; Griffiths RR. (2017)

Neuronal dynamics of the anterior cingulate cortex during working memory and serotonergic manipulation - Golden C. (Imperial College London, 2016)

Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. - Kraehenmann R. (2016)

Self unbound: ego dissolution in psychedelic experience. - Letheby C; Gerrans P (Neuroscience of consciousness, 2016)

Clinical potential of psilocybin as a treatment for mental health conditions. - Daniel J; Haberman M. (2016)

Psychedelics as Medicines: An Emerging New Paradigm. - Nichols DE; Johnson MW; Nichols CD. (2016)

Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. - Nutt D. (2016)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. - Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; et al. (2016)

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. - Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA. (2016)

Psilocybin: Psychotherapy or drug? - Goodwin GM. (2016)

Psilocybin in end of life care: Implications for further research. - Summergrad P. (2016)

Psilocybin and palliative end-of-life care. - Shelton RC; Hendricks PS. (2016)

Psilocybin for depression and anxiety associated with life-threatening illnesses. - McCorvy JD; Olsen RH; Roth BL. (2016)

The role of psychedelics in palliative care reconsidered: A case for psilocybin. - Kelmendi B; Corlett P; Ranganathan M; D'Souza C; Krystal JH. (2016)

Psilocybin-assisted psychotherapy for dying cancer patients - aiding the final trip. - Spiegel D. (2016)

Psilocybin: promising results in double-blind trials require confirmation by real-world evidence. - Breckenridge A; Grobbee DE. (2016)

Statistical comparison of mass spectra for identification of amphetamine-type stimulants. - Bodnar Willard MA; McGuffin VL; Smith RW. (2016)

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. - Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR. (2016)

Psychedelics in the treatment of unipolar mood disorders: a systematic review. - Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH. (2016)

Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging. - Dos Santos RG; Osório FL; Crippa JAS; Hallak JEC. (2016)

Role of psilocybin in the treatment of depression. - Mahapatra A; Gupta R. (2016)

Alterations of consciousness and mystical-type experiences after acute LSD in humans. - Liechti ME; Dolder PC; Schmid Y. (2016)

[New patterns of substance use and abuse among French adolescents, a knowledge synthesis]. - Jeanne G; Purper-Ouakil D; Rigole H; Franc N. (2016)

Psilocybin: panacea or placebo? - Hendrie C; Pickles A. (2016)

Question-based Drug Development for psilocybin. - Dijkstra FM; Jacobs GE; Cohen AF. (2016)

Question-based Drug Development for psilocybin - Authors' reply. - Carhart-Harris RL; Nutt DJ. (2016)

Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. - Dasgupta A. (2016)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. - Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR. (2016)

It's time to take psilocybin seriously as a possible treatment for substance use disorders. - Bogenschutz MP. (2016)

Return of the psychedelics: Psilocybin for treatment resistant depression. - Patra S. (2016)

Psilocybin for treating substance use disorders? - de Veen BT; Schellekens AF; Verheij MM; Homberg JR. (2016)

Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics. - Tófoli LF; de Araujo DB. (2016)

Long-term follow-up of psilocybin-facilitated smoking cessation. - Johnson MW; Garcia-Romeu A; Griffiths RR. (2016)

Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans. - Maqueda AE; Valle M; Addy PH; Antonijoan RM; Puntes M; Coimbra J; Ballester MR; Garrido M; González M; Claramunt J; Barker S; Lomnicka I; et al. (2016)

Hallucinogen Use Disorders. - Hardaway R; Schweitzer J; Suzuki J (Child and adolescent psychiatric clinics of North America, 2016)

Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor. - Howland RH. (2016)

ChemInform Abstract: Observations Concerning the Synthesis of Tryptamine Homologues and Branched Tryptamine Derivatives via the Borrowing Hydrogen Process: Synthesis of Psilocin, Bufotenin, and Serotonin. - Bartolucci Silvia; Mari Michele; Di Gregorio Giovanni; Piersanti Giovanni (ChemInform, 2016)

[Trends in Abuse of Biogenic Drugs in Parts of Germany 2007-2013]. - Pietsch J; Scheffel K; Acquarone D; Koch I; Deters M; Hermanns-Clausen M. (2016)

Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. - Tylš F; Páleníček T; Kadeřábek L; Lipski M; Kubešová A; Horáček J. (2016)

PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG - Tyls F; Michaela Viktorinova T; Prokopcova D; Korcak J; Androvicova R; Brunovsky M; Horacek J. (2016)

PM502. Effect of psilocybin on EEG brain connectivity in healthy volunteers - preliminary report - Palenicek T; Tyls F; Viktorinova M; Prokopcova D; Korcak J; Androvicova R; Brunovsky M; Horacek J. (2016)

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. - Rickli A; Moning OD; Hoener MC; Liechti ME. (2016)

Commentary: Effects of psilocybin on time perception and temporal control of behavior in humans. - Shebloski KL; Broadway JM. (2016)

Sixty seconds on... psilocybin. - Hawkes N. (2016)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. - Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; et al. (2016)

Altered states: psilocybin for treatment-resistant depression. - Cowen P. (2016)

Observations concerning the synthesis of tryptamine homologues and branched tryptamine derivatives via the borrowing hydrogen process: synthesis of psilocin, bufotenin, and serotonin - Bartolucci Silvia; Mari Michele; Di Gregorio Giovanni; Piersanti Giovanni (Tetrahedron, 2016)

Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. - Preller KH; Pokorny T; Hock A; Kraehenmann R; Stämpfli P; Seifritz E; Scheidegger M; Vollenweider FX. (2016)

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. - Mithoefer MC; Grob CS; Brewerton TD. (2016)

Psychedelics. - Nichols DE. (2016)

DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in "grow-kits" seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin. - Gambaro V; Roda G; Visconti GL; Arnoldi S; Casagni E; Dell'Acqua L; Farè F; Paladino E; Rusconi C; Arioli S; Mora D. (2016)

Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models. - Kyzar EJ; Kalueff AV. (2016)

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. - Dos Santos RG; Osório FL; Crippa JA; Riba J; Zuardi AW; Hallak JE. (2016)

[Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning]. - Suzuki K. (2016)

Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior - Johns Hopkins University (ClinicalTrials.gov, 2016)

Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache. - Davenport WJ. (2016)

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. - Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX. (2016)

The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving. - Sweat NW; Bates LW; Hendricks PS (Journal of psychoactive drugs, 2015)

HPLC Analysis of Hallucinogenic Mushroom Alkaloids (Psilocin and Psilocybin) Applying Hydrophilic Interaction Chromatography (HILIC) - Nagy Julia; Veress Tibor (Journal of Forensic Research, 2015)

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. - Schindler EA; Gottschalk CH; Weil MJ; Shapiro RE; Wright DA; Sewell RA. (2015)

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. - Barrett FS; Johnson MW; Griffiths RR. (2015)

A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State. - Lowe LM; Peterson BL; Couper FJ. (2015)

Lysergic Acid Diethylamide and Psilocybin Revisited. - Geyer MA. (2015)

[Psilocybin - public available psychodysleptic]. - Dydak K; Śliwińska-Mossoń M; Milnerowicz H. (2015)